Searchable abstracts of presentations at key conferences on calcified tissues

ba0003pp214 | Osteoporosis: evaluation and imaging | ECTS2014

Bone marrow densitometry by clinical high resolution computed tomography of human vertebrae

Pena Jaime , Campbell Graeme , Damm Timo , Barkmann Reinhard , Waldhausen Sonja , Thomsen Felix , Krause Matthias , Puschel Klaus , Gluer Claus C

Bone mineral density (BMD) as measured by quantitative computed tomography (QCT) is biased by the variable marrow composition since marrow fat reduces the apparent BMD. We developed a marrow densitometry (MD) method that identifies subvolumes in the vertebrae that consist of bone marrow only (bone voids) and determines their average mineral equivalent density values. The method was developed for use with in vivo high resolution QCT (HR-QCT). HR-QCT still has limited s...

ba0006oc23 | (1) | ICCBH2017

Sustained radiographic and functional improvements with asfotase alfa treatment from up to 7 years in children with hypophosphatasia

Whyte Michael P. , Rockman-Greenberg Cheryl , Moseley Scott , Denker Andrew E. , McAlister William H.

Objective: Children with hypophosphatasia (HPP) treated with asfotase alfa in a Phase 2 study (NCT00952484) and its open-label extension (NCT01203826) experienced significant improvements in skeletal mineralization and physical function that were sustained through 5 years of treatment (1). Herein, we report data from these studies with a maximum of 7 years of treatment.Methods: Children with HPP aged 6–12 years at baseline received asfotase alfa (3 ...

ba0001pp31 | Bone biomechanics and quality | ECTS2013

A GWAS in an extreme high bone mass population shows excess signal from genes associated with BMD in the normal population

Gregson Celia L , Leo Leo Paul J , Clark Graeme R , Smith George Davey , Brown Matthew A , Tobias Jon H , Duncan Duncan Emma L

Extreme high bone mass (HBM) may be monogenic (e.g. due to mutations in SOST or LRP5) or polygenic, due to variants in the same genes determining bone mineral density (BMD) as found in the general population. We aimed to determine the genetic cause underlying HBM in an extreme HBM population.258 unexplained HBM cases (defined as L1 Z-score ≥+3.2 plus total hip Z-score ≥+1.2, or total hip Z-score ≥+3.2 and L1 <...

ba0001pp245 | Cell biology: osteocytes | ECTS2013

IGF1 regulates MC-3T3 and human primary osteoblast to osteocyte differentiation in 3D culture

Scully Nicole E E , Mason Deborah J , Evans Bronwen A J

Osteocytes differentiate from osteoblasts, are embedded in mineralised matrix and are critical regulators of bone remodelling. In vitro osteocyte models are limited to cell lines in monolayer, which do not represent their 3D environment in vivo. We have shown that osteoblasts in 3D gels differentiate along the osteocytic pathway. Since IGF1 regulates osteoblasts, and is involved in osteocyte response to mechanical loading, we hypothesised that IGF1 modulates ...

ba0004p20 | (1) | ICCBH2015

Bone mineral density in patients with autosomal recessive osteopetrosis after hematopoietic cell transplantation

Petryk Anna , Polgreen Lynda E , Dengel Donald R , Defor Todd E , Orchard Paul

Objectives: Autosomal recessive osteopetrosis (OP) is a rare metabolic bone disease characterized by impaired osteoclast function resulting in defective bone resorption and generalized high bone mineral density (BMD). Excessive bone compromises bone marrow space, leading to marrow failure. The infantile malignant form is typically fatal within the first decade of life. The intermediate form presents later during childhood. Currently, the only potential curative therapy for OP ...

ba0005p339 | Osteoporosis: pathophysiology and epidemiology | ECTS2016

High prevalence of reduced bone mineral density and undertreatment of osteoporosis in patients with systemic sclerosis

Spanjer Moon J , Bultink Irene E M , Voskuyl Alexandre E , Lems Willem F

Purpose: Systemic sclerosis (SSc) is a rare inflammatory rheumatic disease that has been associated with an increased risk of low bone mineral density (BMD). However, data on risk factors associated with bone loss in SSc are scarce. The objective of this study was to investigate the prevalence of and the risk factors for low BMD in patients with SSc.Methods: Cross-sectional data of 61 patients with SSc were collected. BMD in the lumbar spine, total hip a...

ba0003pp331 | Osteoporosis: treatment | ECTS2014

Prevalence of osteoporosis treatment depending on the risk evaluation of the osteoporotic fractures in patients with rheumatoid arthritis in Russia

Dydykina Irina , Vetkova Elizaveta , Podvorotova Marina , Taskina E , Smirnov A , Sinenko A , Ruskina T , Peshekhonov D , Myasoedova S , Zavodovski B , Dydykina P , Petrova E , Zhigulin V , Alekseeva L , Nasonov E

Background: It is known that one of the features of rheumatoid arthritis (RA) is a generalized bone loss, therefore important tasks for the physician are timely evaluating of the risk of fractures and approving osteoporosis treatment in patients with RA.Objectives: Through the Programme of the Russian Association of Rheumatology for the diagnosis, prevention and treatment osteoporosis (OP) in patients with RA we evaluated the 10 year probability of major...

ba0001pp266 | Chondrocytes and cartilage | ECTS2013

The Rho/ROCK GTPase pathway differentially modulates chondrocyte and osteoblast differentiation from pluripotent stem cells

Bukhary Dalea M , McDonald Fraser , Grigoriadis Agamemnon E

It is well-established that in vitro differentiation of embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) can recapitulate embryonic development through germ layer induction, enrichment and expansion of specific lineages. We have used PSC technology and developed a novel, mESC differentiation system for investigating the mechanisms of chondrocyte and osteoblast lineage commitment and differentiation. This step-wise, serum-free protocol uses specif...